U.S. Non-oncology Biopharmaceuticals Market – Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

U.S. Non-oncology Biopharmaceuticals Market – Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Biopharmaceuticals are complex, high molecular weight proteins and peptides that are produced or synthesized from living biological source. Biopharmaceuticals are further divided into biologics and biosimilars.
Biologics can be defined as molecules derived from the living cells such as microorganisms, or plant or animal cells and used in the treatment, diagnosis, or prevention of diseases. Most of the biologic molecules are very large, complex molecules, or mixture of molecules. The U.S. Food and Drug Administration (FDA) defines biosimilar as a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.
Non-oncology biopharmaceuticals are drugs which are indicated for treatment of a number of diseases except cancer such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, hemophilia, age-related macular degeneration, osteoporosis, and others.
Market Dynamics
Frequent launch, approval, and presence of robust pipeline of novel biopharmaceutical products indicated for treatment of number of non-oncology indication is expected to drive the U.S. non-oncology biopharmaceuticals market growth over the forecast period. For instance, in November 2018, Swedish Orphan Biovitrum AB and Novimmune SA received the U.S. Food and Drug Administration (FDA) approval for Gamifant (emapalumab-lzsg), an interferon gamma (IFNγ) blocking antibody for the treatment of pediatric (new born and older) and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy.
In March 2018, Theratechnologies Inc. and its partner TaiMed Biologics Inc. received the U.S. Food and Drug Administration (FDA) approval for its Trogarzo (ibalizumab-uiyk) Injection. In combination with other ARTs, Trogarzo is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection, who are failing their current antiretroviral regimen.
Key players in the market are adopting inorganic growth strategies such as mergers and partnerships for the development of novel products or to expand their product portfolio by acquisition. Such frequent activities by key players is expected to significantly support the U.S. non-oncology biopharmaceuticals market growth over the forecast period.
For instance, in 2016, Teva Pharmaceutical Industries Ltd. and Celltrion Inc. entered into an exclusive partnership to commercialize two of Celltrion’s mAb biosimilar candidates in the U.S. and Canada.
In 2016, Shire plc. and Baxalta Incorporated entered into an agreement, under which Shire will combine with Baxalta. Baxalta has a well-established hematology portfolio based on its heritage and legacy of leadership in hemophilia. With this merger, the established company (Shire plc.) will strengthen its position in the market.
Furthermore, high prevalence of various chronic disorders such as diabetes, asthma, cardiovascular diseases, and arthritis in the U.S. is expected to increase demand for biopharmaceutical products and in turn support the non-oncology biopharmaceuticals market growth. For instance, according to the data published by Centers for Disease Control and Prevention (CDC), in 2021, over 100 million U.S. adults were suffering from diabetes or pre-diabetes.
Key features of the study:
This report provides in-depth analysis of U.S. non-oncology biopharmaceuticals market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights into market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
It profiles key players in the U.S. Non-oncology biopharmaceuticals market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include, Sanofi S.A., Pfizer, Inc., Johnson & Johnson, Novartis International AG, Amgen, Inc., Eli Lilly and Company, AbbVie Inc., Bristol - Myers Squibb Company, F. Hoffmann-La Roche AG, Novo Nordisk A/S, GlaxoSmithKline plc., UCB Pharma, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Ltd, AstraZeneca Plc, Mylan N.V., LEO Pharma A/S, Boehringer Ingelheim GmbH, Alexion Pharmaceuticals Inc., Merck & Co., Inc., Elusys Therapeutics, Inc., Swedish Orphan Biovitrum AB, Samsung Bioepis NL B.V., Biogen Inc., and Theratechnologies Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The U.S. non-oncology biopharmaceuticals market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the U.S. non-oncology biopharmaceuticals market
Detailed Segmentation:
U.S. Non-oncology Biopharmaceuticals Market, By Product Type :
Biologics
Biosimilars
U.S. Non-oncology Biopharmaceuticals Market, By Drug Class:
Monoclonal Antibody
Enzyme Replacement Therapy
Erythropoietin
Interferon
Colony-stimulating Factor
Botulinum Toxin
Fusion Protein
Vaccines
Human Recombinant Insulin
Blood Factors
Human Growth Hormone
Others
U.S. Non-oncology Biopharmaceuticals Market, By Disease Indication:
Diabetes
Rheumatoid Arthritis
Psoriatic Arthritis
Multiple Sclerosis
Hemophilia
Anemia
Age-related Macular Degeneration
Hepatitis B
Cystic Fibrosis
Osteoporosis
Crohn’s Disease
Ulcerative Colitis
Psoriasis
Ankylosing Spondylitis
Others (Cardiac diseases and others)
Company Profiles
Sanofi S.A.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Pfizer, Inc.
Johnson & Johnson
Novartis International AG
Amgen, Inc.
Eli Lilly and Company
AbbVie Inc.
Bristol - Myers Squibb Company
F. Hoffmann-La Roche AG
Novo Nordisk A/S
GlaxoSmithKline plc.
UCB Pharma
Teva Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Ltd
AstraZeneca Plc
Mylan N.V.
LEO Pharma A/S
Boehringer Ingelheim GmbH
Alexion Pharmaceuticals Inc.
Merck & Co., Inc.
Elusys Therapeutics, Inc.
Swedish Orphan Biovitrum AB
Samsung Bioepis NL B.V.
Biogen Inc.
Theratechnologies Inc.
“*” marked represents similar segmentation in other categories in the respective section.